{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:17:19Z","timestamp":1768306639553,"version":"3.49.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human Epidermal Growth Factor Receptor 2 (HER2), a component of the epidermal growth factor receptor family, is thought to be related to advanced prostate cancer (PCa) when overexpressed. Currently, most research on HER2 is limited to molecular pathology, with relatively few studies focused on imaging aspects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To develop a predictive model by extracting high-throughput radiomics features from magnetic resonance imaging and combining them with clinical characteristics for predicting HER2 overexpression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A total of 201 patients who underwent radical prostatectomy and HER2 immunohistochemistry were retrospectively enrolled. These patients were randomly divided into a training set (n=160) and a test set (n=41). Multimodal radiomics features extracted from T2-weighted imaging (T2WI) and apparent diffusion coefficient maps (ADC) were selected using Mann-Whitney U test and least absolute shrinkage and selection operator (LASSO) with ten-fold cross-validation. Predictive models were developed and evaluated based on discrimination and clinical utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The combined model integrating ISUP Grade, PSA and Radscore achieved an area under the curve (AUC) of 0.841 (95% CI: 0.697-0.955) in the test set, significantly outperforming the clinical model (AUC = 0.580;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.02, DeLong test) and demonstrating a modest improvement over the Radscore model (AUC = 0.838 (0.693-0.951). Evaluation results showed consistent discriminatory power: 0.78 accuracy, 0.77 sensitivity, and 0.79 specificity, indicating well-balanced performance between positive and negative classes. Decision curve analysis and Waterfall plot demonstrated strong clinical applicability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combined model effectively predicts HER2 overexpression in prostate cancer, with potential to inform more personalized treatment strategies for HER2-overexpressing PCa patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1707946","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:36:05Z","timestamp":1768286165000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting HER2 overexpression in prostate cancer using machine learning: implications for personalized therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Xuantong","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: A review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4103\/aja202417","article-title":"Prostate cancer: screening and early detection","volume":"26","author":"Caffo","year":"2024","journal-title":"Asian J Androl"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/0969141321989738","article-title":"Impact of cancer screening on metastasis: A prostate cancer case study","volume":"28","author":"Lange","year":"2021","journal-title":"J Med Screen"},{"key":"B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00322-0","article-title":"Antitumour immunity regulated by aberrant ERBB family signalling","volume":"21","author":"Kumagai","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","article-title":"EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment","volume":"19","author":"Friedlaender","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2023.152219","article-title":"The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma","volume":"67","author":"Estephan","year":"2023","journal-title":"Ann Diagn Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.3390\/cancers13071688","article-title":"Expression of ERBB family members as predictive markers of prostate cancer progression and mortality","volume":"13","author":"Clairefond","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/0008-5472.CAN-16-1656","article-title":"HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone","volume":"77","author":"Day","year":"2017","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6014","DOI":"10.3390\/cancers13236014","article-title":"Her2 expression in circulating tumor cells is associated with poor outcomes in patients with metastatic castration-resistant prostate cancer","volume":"13","author":"Maillet","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2546","article-title":"Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer","volume":"16","author":"Minner","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.5235","article-title":"HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method","volume":"12","author":"Sharifi","year":"2016","journal-title":"Oncol Lett"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","article-title":"Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches","volume":"27","author":"Sekhoacha","year":"2022","journal-title":"Molecules"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/app142310947","article-title":"Artificial intelligence and statistical models for the prediction of radiotherapy toxicity in prostate cancer: A systematic review","volume":"14","author":"Piras","year":"2024","journal-title":"Appl Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-023-00444-9","article-title":"Recent advances and future perspectives in the therapeutics of prostate cancer","volume":"12","author":"Varaprasad","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-01409","article-title":"Response of human epidermal growth factor receptor 2-expressing prostate cancer to trastuzumab deruxtecan","volume":"177","author":"Lap","year":"2024","journal-title":"Ann Intern Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-panTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.09.24302395","article-title":"Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition","author":"Wilkinson","year":"2024","journal-title":"medRxiv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.12.014","article-title":"Recent advances in HER2-targeted delivery for cancer therapy","volume":"26","author":"Dhritlahre","year":"2021","journal-title":"Drug Discov Today"},{"key":"B20","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.3390\/jcm12237322","article-title":"Multi-institutional development and validation of a radiomic model to predict prostate cancer recurrence following radical prostatectomy","volume":"12","author":"Huynh","year":"2023","journal-title":"J Clin Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phro.2023.100530","article-title":"Robustness of magnetic resonance imaging and positron emission tomography radiomic features in prostate cancer: Impact on recurrence prediction after radiation therapy","volume":"29","author":"Dutta","year":"2024","journal-title":"Phys Imaging Radiat Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.3390\/cancers15184536","article-title":"MRI radiomics-based machine learning models for ki67 expression and gleason grade group prediction in prostate cancer","volume":"15","author":"Qiao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1186\/s12885-023-11130-8","article-title":"Deep learning-based radiomic nomograms for predicting Ki67 expression in prostate cancer","volume":"23","author":"Deng","year":"2023","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.29186","article-title":"Association of pathological features and multiparametric MRI-based radiomics with TP53-mutated prostate cancer","volume":"60","author":"Chen","year":"2024","journal-title":"J Magn Reson Imaging"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e222646","DOI":"10.1148\/radiol.222646","article-title":"Multiparametric MRI and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers","volume":"308","author":"Ramtohul","year":"2023","journal-title":"Radiology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10641-7","article-title":"Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics","volume":"34","author":"Zheng","year":"2024","journal-title":"Eur Radiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/app151910665","article-title":"Deep learning strategies for semantic segmentation in robot-assisted radical prostatectomy","volume":"15","author":"Sibilano","year":"2025","journal-title":"Appl Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3390\/life14060751","article-title":"A review of advances in molecular imaging of rheumatoid arthritis: from in vitro to clinic applications using radiolabeled targeting vectors with technetium-99m","volume":"14","author":"Ali","year":"2024","journal-title":"Life (Basel)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.3390\/cancers15225452","article-title":"The development and external validation of artificial intelligence-driven MRI-based models to improve prediction of lesion-specific extraprostatic extension in patients with prostate cancer","volume":"15","author":"van den Berg","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-10427-3","article-title":"Radiomics for the identification of extraprostatic extension with prostate MRI: a systematic review and meta-analysis","volume":"34","author":"Ponsiglione","year":"2024","journal-title":"Eur Radiol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1707946\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:36:06Z","timestamp":1768286166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1707946\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":30,"alternative-id":["10.3389\/fonc.2025.1707946"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1707946","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"article-number":"1707946"}}